In a report released yesterday, Rick Wise from Stifel Nicolaus maintained a Buy rating on LivaNova (LIVN – Research Report), with a price target of $65.00. The company’s shares closed yesterday at $58.45.
Wise covers the Healthcare sector, focusing on stocks such as Masimo, Zimmer Biomet Holdings, and Viewray. According to TipRanks, Wise has an average return of 8.2% and a 62.79% success rate on recommended stocks.
In addition to Stifel Nicolaus, LivaNova also received a Buy from Wolfe Research’s Michael Polark in a report issued on July 27. However, on the same day, Mizuho Securities maintained a Hold rating on LivaNova (NASDAQ: LIVN).
See Insiders’ Hot Stocks on TipRanks >>
LIVN market cap is currently $3.11B and has a P/E ratio of -31.83.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LIVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The Other segment consists of company’s shared service expenses for finance, legal, human resources, information technology, and new ventures. Its products include VNS therapy system. oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, and cannulae. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.
Read More on LIVN:
